EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
|Articles|February 1, 2004
Less AD in adult populations
Anaheim Hills, Calif. - The new topical immunomodulators (TIMs) such as pimecrolimus (Elidel) and tacrolimus (Protopic) will reverse the growing number of cases of adult atopic dermatitis, predicts Cheryl Effron, M.D., a dermatologist in Anaheim Hills, Calif.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Remibrutinib for Symptomatic Dermographism
2
Abrocitinib Reduces Pathogenic Skin-Resident Memory T Cells in Atopic Dermatitis
3
Personalized Prescription Skin Care: Curology’s Whitney Tolpinrud, MD, on the Evolution of Virtual Dermatology
4
Previewing the 2026 Fall Clinical Dermatology Conference
5